This anti-myostatin fusion was shown to increase skeletal growth in pre-clinical models of DMD [88] and healthy humans [89] and is now in an ongoing phase 2 investigation for treatment of DMD [90]. Here, MSTN is linked to Duchenne muscular dystrophy.